ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
ReShape Lifesciences Inc

ReShape Lifesciences Inc (RSLS)

0.1958
-0.0081
(-3.97%)
Closed June 16 4:00PM
0.1917
-0.0041
(-2.09%)
After Hours: 7:59PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
0.1917
Bid
0.181
Ask
0.235
Volume
624,092
0.192 Day's Range 0.2099
0.1414 52 Week Range 2.448
Market Cap
Previous Close
0.2039
Open
0.1978
Last Trade
1
@
0.1937
Last Trade Time
Financial Volume
$ 123,627
VWAP
0.198092
Average Volume (3m)
5,609,706
Shares Outstanding
23,457,047
Dividend Yield
-
PE Ratio
-0.39
Earnings Per Share (EPS)
-0.49
Revenue
8.68M
Net Profit
-11.39M

About ReShape Lifesciences Inc

Reshape Lifesciences Inc is a developer of minimally invasive medical devices to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, the ReShape Vest, an investigational device, to help treat more patients with obesity, a... Reshape Lifesciences Inc is a developer of minimally invasive medical devices to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, the ReShape Vest, an investigational device, to help treat more patients with obesity, and ReShapeCare, a virtual coaching program delivered through an app. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Headquarters
Wilmington, Delaware, USA
Founded
1970
ReShape Lifesciences Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker RSLS. The last closing price for ReShape Lifesciences was $0.20. Over the last year, ReShape Lifesciences shares have traded in a share price range of $ 0.1414 to $ 2.448.

ReShape Lifesciences currently has 23,457,047 shares outstanding. The market capitalization of ReShape Lifesciences is $4.46 million. ReShape Lifesciences has a price to earnings ratio (PE ratio) of -0.39.

RSLS Latest News

ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update

Commercial Launch of Next-Generation Lap-Band® 2.0 FLEX Continues Significant Reduction in Overall Operating Expenses of 51% in the First Quarter of 2024 Compared to the First Quarter of 2023...

ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update

IRVINE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it...

ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update

Completed First Surgeries With Next-Generation Lap-Band® 2.0 FLEX 2024 Operating Expenses Expected to Decrease by more than 50% Compared to 2023; Reaffirming Commitment to Profitability...

ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System

IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that the...

ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX

2024 Operating Expenses Expected to Decrease by 55.4% Compared to 2023 Company Reaffirms Commitment to Profitability High Priority Search for Synergistic M&A Partner Continues IRVINE, Calif...

ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX

FLEX Technology Designed to Enhance the Patient Experience Surgeon Training Underway for the Initial Launch of the Lap-Band® 2.0 FLEX IRVINE, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ReShape...

ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX

IRVINE, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0383-16.6521739130.230.23080.185510459680.20635985CS
40.00170.8947368421050.190.50.1714165151630.25909357CS
120.01911.00173711640.17270.50.15856097060.25603918CS
26-0.1949-50.41386445940.38660.50.141434157490.25817361CS
52-2.1583-91.84255319152.352.4480.141435188460.30905298CS
156-474.8083-99.95964210534754750.1414185590058.91454732CS
260-474.8083-99.95964210534754750.1414185590058.91454732CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
KAVLKaival Brands Innovations Group Inc
$ 5.96
(338.24%)
70.99M
LRHCLa Rosa Holdings Corporation
$ 1.165
(90.61%)
40.6M
SVMHSRIVARU Holding Ltd
$ 0.227586
(49.24%)
276.03M
BRFHBarfresh Food Group Inc
$ 3.03
(38.36%)
247.31k
NNENano Nuclear Energy Inc
$ 9.37
(32.53%)
1.77M
NXLNexalin Technologies Inc
$ 0.89
(-35.52%)
3.93M
INABIN8bio Inc
$ 1.095
(-34.82%)
4.92M
QXOQXO Inc
$ 134.10
(-34.71%)
142.29k
GANXGain Therapeutics Inc
$ 1.24
(-34.39%)
3.09M
KYTXKyverna Therapeutics Inc
$ 9.52
(-34.07%)
4.31M
NVDANVIDIA Corporation
$ 131.88
(1.75%)
309.34M
SVMHSRIVARU Holding Ltd
$ 0.227586
(49.24%)
276.03M
KITTNauticus Robotics Inc
$ 0.1921
(19.69%)
165.83M
CRKNCrown Electrokinetics Corporation
$ 0.0582
(-21.35%)
136.77M
SQQQProShares UltraPro Short QQQ
$ 8.43
(-1.29%)
112.46M

RSLS Discussion

View Posts
Money hunt Money hunt 3 days ago
230k Bo to shabby dude!!! i’m almost there
👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 3 days ago
$RSLS >>> Thin AF!!!







$RSLS >>> Shares Outstanding: 23,457,090
Insider Shares: 17,566,310
Insider Ownership: 74.89%(!)
Total Insiders: 76(!)
Link: https://fintel.io/sn/us/rsls



$$$RSLS$$$
👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 3 days ago
Hell YES!!! Added more than 1% of $RSLS's O/S so far...

>>> for the LONGHAUL!!!

...how about you?

...this will blow up like crazy very shortly, bro!







$$$RSLS$$$
👍️0
MetaMonster MetaMonster 4 days ago
Chomp chomp chomp those cheapies
👍️0
Money hunt Money hunt 4 days ago
Short squeeze up ahead with clear blue skies dude!!!!
👍️0
Money hunt Money hunt 4 days ago
I see dude…..1$ for starters would send it.. .30 walls must be busted down
👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 4 days ago
$RSLS >>> Watch this beautiful 50MA/100MA GOLDEN CROSS!!!





$$$RSLS$$$
👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 4 days ago
$RSLS >>> LT-Chart with Acc./Dist.-Ind. (@-425.2m!!!), remember O/S is only @23.46m! Squeeze!?



$$$RSLS$$$
👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 4 days ago
$RSLS >>> $10+/Share would be a fair valuation...


...but cud also blow up to $50 - $100+


Watch LT-Chart (daily) with Acc./Dist.-Indicator and know what I mean! ;)
👍️0
Money hunt Money hunt 4 days ago
It’s going to roar like RNAZ$$$
👍️0
Money hunt Money hunt 4 days ago
Hell yes dude!! Big time $$$$$
👍️0
stressfreeliving stressfreeliving 4 days ago
Will keep this on my radar. Thanks.
👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 4 days ago
$RSLS >>> Insider Ownership: 74.89%(!) Total Insiders: 76(!) $$$$$$$$
👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 4 days ago
$RSLS @.20 >>> LOADING-ZONE!!! DYOR. *NFA
👍️0
stressfreeliving stressfreeliving 4 days ago
Hoping around stocks. Holding short term.
👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 4 days ago
I'll add some more tmrw as soon my additional funds arrived. $RSLS
👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 4 days ago
Where are you, dude!? $RSLS about to blow up... ;)

#PRIMED
👍️0
Invest-in-America Invest-in-America 4 days ago
RSLS: GOOD!!
👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 4 days ago
$RSLS >>> VOLUME SURGE!!!
👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 4 days ago
Bidding for a few more down here...


...only little partial fills so far.
👍️0
Money hunt Money hunt 5 days ago
The dip is inn dude!!! Now let’s rippppppppp!!!
👍️0
Money hunt Money hunt 5 days ago
Hell yes dude!!!!
👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 5 days ago
$RSLS >>> CTB up to 260%!!!



$$$RSLS$$$
👍️0
Money hunt Money hunt 5 days ago
Hell yes dude!!! I’m ready with the clan!!!
👍️0
Invest-in-America Invest-in-America 6 days ago
RSLS: Yep; & TOUGH overall Market today --- anywhere one looks.
👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 6 days ago
Finally, the recent (upward) gap has been closed. $RSLS
👍️0
Invest-in-America Invest-in-America 6 days ago
RSLS: By all means, Dude!!
👍️0
Invest-in-America Invest-in-America 6 days ago
RSLS: Hah-Hah, Bro!!!
👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 6 days ago
I'll try to add some $.20's & $.21's next week to support the bid & further lower my average. $RSLS





$$$RSLS$$$
👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 6 days ago
LOL! Prepare for glory, master! Very soon...



$$$RSLS$$$
👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 6 days ago
Bingo!



$$$RSLS$$$
👍️0
Invest-in-America Invest-in-America 6 days ago
RSLS: Hot-under-the-COLAR, Homeboy!!! GEEEEEEEE-ZEUS!!! (And I thought I was the ONLY child posting silly --- but nonetheless apropos --- GIF'S!!! LOVE-IT!!!)


That's ME, above, with my new DATE over at her Condo last night!!! I was 'breaking-the-ice', so to speak, with a cute little HIP-HOP-TUNE I just wrote!!!
👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 6 days ago
$RSLS >>> Shares Outstanding: 23,457,090
Insider Shares: 17,566,310
Insider Ownership: 74.89%(!)
Total Insiders: 76(!)
Link: https://fintel.io/sn/us/rsls



$$$RSLS$$$
👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 7 days ago
Paperland incoming for this stock soon enough as I see it, my friend. $RSLS

Easy buy, add & hold imo. *NFA

Little more PAYtience lads & gents, we're very close to move north hard.



$$$RSLS$$$
👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 7 days ago
$RSLS >>> https://microcaps.com/srax-spotlight/sequire-spotlight-presents-reshape-lifesciences-rsls-health-wellness-with-innovative-solutions/
👍️0
Money hunt Money hunt 1 week ago
Always ready for big news hitting international wires dude!!!
👍️ 1
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 2 weeks ago
Get ready... ;)

👍️0
stressfreeliving stressfreeliving 2 weeks ago
Appreciate all the DD you bring here.
👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 2 weeks ago
$RSLS >>> 1Y-Chart~


180day-Chart~


LT-Chart~


$$$RSLS$$$
👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 2 weeks ago
$RSLS @$.2499 >>> 2x FDA greenlight!!! $$$$$$$





$$$RSLS$$$
👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 2 weeks ago
You're welcome, buddy.
👍️0
Invest-in-America Invest-in-America 2 weeks ago
RSLS: THANKS for the reminder, Dude!!
👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 2 weeks ago
$RSLS >>> Looking for partners!



Link: https://ir.reshapelifesciences.com/news-releases/news-release-details/reshape-lifesciencesr-engages-maxim-group-llc-identify-strategic
👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 2 weeks ago
$RSLS >>> ReShape Lifesciences Inc. (RSLS) Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation Device

ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company was awarded a $331,541 Small Business Innovation Research (SBIR) grant for the development of ReShape’s Diabetes Bloc-Stim Neuromodulation™ (DBSN™) device, which utilizes its proprietary vagus nerve block (vBloc) technology platform, combined with vagus nerve stimulation, for the treatment of Type 2 diabetes, a prominent disorder associated with obesity. Specifically, the grant will fund the exploration of high-resolution endoscopic ultrasound (EUS) probes to aid accurate placement of the electrodes laparoscopically on the celiac and hepatic branches in large animals.

“ReShape’s DBSN™ device selectively modulates vagal block and stimulation to the liver and pancreas to manage blood glucose. Increased glycemic control, has been successfully demonstrated in a Zucker rat model of Type 2 diabetes as well as in an alloxan treated swine model of type 2 diabetes, both of which were completed with the help of an initial NIH grant,” stated Jonathan Waataja, Ph.D. Director of Research at ReShape Lifesciences®. “We are currently exploring the device’s ability to treat hypoglycemia. We believe high-resolution EUS probes can be used to quickly and accurately locate the fine branches of the vagus nerve and aid in minimally invasive placements of DBSN™ electrodes and study off target effects during stimulation.”

“Awarding this third NIH SBIR grant brings the total received awards to $900,000, and is a testament to both our non-dilutive funding strategy and the NIH’s strong interest in the development of the novel DBSN™ device and its potential to address the significant, global diabetes market,” stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences®. “With the funding, to date, our team has successfully completed the pre-clinical development of the device, which utilizes bioelectronics to adjust insulin production and manage blood glucose to potentially treat Type 2 diabetes and hypoglycemia. It has also shown that this innovative technology may reduce diabetics’ dependence on medications in a very individualized manner with the goal of reducing costs of treatment and complications that arise from poorly controlled blood glucose and non-compliance with diabetes medications. The promise of the DBSN™ device is evidenced, not only by the volume of NIH funding, but also by the presentation of compelling preclinical evidence at multiple medical conferences. Backed by a strong intellectual property portfolio of 74 issued or pending patents related to vBloc, glucose control, AI and Bluetooth applications, we remain committed to furthering its development through similar NIH grants or potential strategic alliances.”

About Diabetes Bloc-Stim Neuromodulation™ Device

The Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system is a novel therapeutic concept that is implanted minimally invasively and delivers bio-electronic neuromodulation of vagus nerve branches that are innervating organs which regulate plasma glucose. The DBSN™ system stimulates vagus celiac fibers of the pancreas to release insulin during stimulation, while blocking the hepatic vagal branch, innervating the liver, to decrease glucose release and decrease insulin resistance following ligation. The DBSN™ system utilizes a proprietary, reversable and adjustable electrical blockade that we believe is key to the future of personalized medicine. We believe the DBSN™ system is superior to both standalone stimulation of the vagus nerve that has shown mixed results, and vagus nerve ligation that has undesirable effects.

About ReShape Lifesciences®

ReShape Lifesciences® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. ReShapeCare™ is a virtual weight-management program that supports lifestyle changes for all weight loss patients led by board-certified health coaches to help them keep the weight off over time. The recently launched ReShape Marketplace™ is an online collection of quality wellness products curated for all consumers to help them achieve their health goals. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss.
For more information, please visit https://www.reshapelifesciences.com.


CONTACTS

ReShape Lifesciences Investor Contact:
Thomas Stankovich
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com

Investor Relations Contact:
Rx Communications Group
Michael Miller
(917)-633-6086
mmiller@rxir.com

Link: https://www.streetinsider.com/dr/news.php?id=22160985
👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 2 weeks ago
$RSLS >>> More DD

Usefulness of the ReShape intragastric balloon for obesity

Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6541059/

👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 2 weeks ago
$RSLS >>> Patent issued last week!

ReShape Gastric Balloon
The Non-Surgical Weight Loss Procedure.




New dual balloon technology


1 year of comprehensive coaching


Proven weight loss without surgery


The ReShape Procedure is a new, FDA approved, non-surgical approach to weight loss that is proven to help people achieve and maintain significant weight loss. It is completely different from any diet, program, or procedure you may have tried or considered before. The ReShape Procedure was specifically designed for patients with a lower BMI (between 30–40). ReShape may be a good weight loss option for people who do not qualify or do not want surgery.

With ReShape, two connected balloons filled with saline (salt water) are placed temporarily inside your stomach in an outpatient medical setting. The procedure lasts about 20 minutes while you are comfortably sedated under light anesthesia. An endoscope is used to insert the balloons into the stomach, and saline is used to inflate the balloons when they are properly positioned. Once the balloons are inflated, the endoscope is removed and the insertion procedure is complete. The balloons remain in the stomach for 6 months.

When filled with saline, the balloons help you lose weight and encourage healthy eating habits by taking up room in your stomach, so there is less space for food. You can still eat the healthy foods you enjoy, but the balloons act as built-in portion control, helping you feel full and less hungry.

After six months, the balloons are deflated and removed during a similar endoscopic procedure.


Dual-Balloon Technology

Only the ReShape Procedure places two connected, medical-grade and saline-filled balloons inside your stomach for six months. The ReShape Integrated Dual Balloon is designed to take up room in your stomach, which creates a feeling of fullness and may help you feel satisfied with less food. The dual balloon is designed to conform to the curvature of the stomach for comfort, and also includes an anti-migration feature, so if one balloon deflates, the second balloon prevents the device from passing into the intestines for increased safety.



Gastric Balloon

The balloon placement is completed endoscopically, without surgery, in an outpatient setting. There are no incisions, scars, or permanent changes to your digestive system. The procedure is completely reversible, and patients are often able to return to work and normal activities in just a few days.

The balloons are a weight loss jump-start. Many patients experience rapid weight loss initially, providing the motivation required to keep going and make the changes stick. You also receive a full year of personalized coaching to support your success and help you make the changes that will encourage a lifetime of healthy living.



One Year of Comprehensive Coaching and Support

ReShape combines the portion-controlling benefits of the balloons with comprehensive coaching to change your eating habits, enhance your physical fitness, and help you adopt a healthy lifestyle that supports long-term success. While the balloons are inside your stomach, you will meet (monthly) with coaches and receive personalized nutrition, fitness, and behavior guidance to help maximize your success. After the balloons are removed, you will continue to meet with your coaching team to make sure that you maintain your healthy lifestyle to reach your goals. With ongoing coaching support, most patients maintain their weight loss or continue to lose weight.



ReShape patient portal

Patients also have access to the ReShape Patient Portal, a comprehensive tool that has everything you need to track your success. The portal includes: weight logging, food logging, activity tracking, goal setting, articles and recipes, community forums, important reminders, and the ability to easily share data with your doctor.

Easy tracking on the go

Access the ReShape Patient Portal from your smartphone or tablet to log and track at your convenience. You can also link your Fitbit® wireless scale and activity tracker to integrate all your weight loss data in one place.

Life-Changing Weight Loss, Without Surgery

ReShape is a proven way to achieve significant weight loss. In a recent study, patients lost more than twice as much weight with ReShape than with diet and exercise alone.1 Most ReShape patients keep the weight off or continue to lose, even after the balloons are removed.

ReShape is a non-surgical procedure. If you do not want or do not qualify for surgery, the ReShape Procedure may be a good option for you.

Ponce J, Woodman G, Swain J, et al; for the REDUCE Pivotal Trial Investigators. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity [published online ahead of print December 16, 2014]. Surg Obes Relat Dis. 2014. doi: 10.1016/j.soard.2014. 12.006.

To learn more about whether ReShape Gastric Balloon may be an effective weight loss treatment for you, or to schedule a consultation with one of our weight loss surgeons, please fill out the form below or call us at (214) 838-7171.

Link: https://www.newyoubariatriccenter.com/reshape-gastric-balloon/
👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 2 weeks ago
$RSLS >>> ReShape Lifesciences signs license agreement with Biorad Medisys for Obalon Gastric BalloonReShape Lifesciences signs license agreement with Biorad Medisys for Obalon Gastric Balloon



ReShape Lifesciences has signed an exclusive, royalty-bearing license agreement with Biorad Medysis (Biorad) to manufacture, commercialise and distribute the Obalon Gastric Balloon System in India, Pakistan, Bangladesh, Nepal, Bhutan, Sri Lanka, and the Maldives.

Based in Mumbai, India, Biorad is an established, science-driven medical device manufacturer that has successfully manufactured and sold innovative medical devices in the urology, gastroenterology, orthopaedic and neurovascular industries, which is now expanding into the bariatric arena.

The license agreement provides $200,000 in upfront payments from Biorad to ReShape and ongoing license payments of 4% on

gross sales of the Obalon Balloon System in the territories. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss.

“This exclusive agreement with Biorad represents the first step towards reintroducing our patented Obalon Balloon System technology to the global marketplace,” said Paul F Hickey, President and Chief Executive Officer of ReShape Lifesciences. “We believe that Biorad, with decades of experience manufacturing and distributing medical devices in the vast South Asia market, potentially reaching approximately 20% to 25% of the world’s population, is an ideal partner to expand the reach of ReShape’s Obalon technology. Our non-surgical, minimally invasive, Obalon System was the first swallowable, gas filled balloon system approved by the US Food and Drug Administration, around which we continue to build a strong intellectual property portfolio. We look forward to a fruitful partnership with Biorad, which we expect will lay the groundwork to catalyse the successful relaunch and joint commercialization of the balloon system in markets world-wide.”

Link: https://www.bariatricnews.net/post/reshape-lifesciences-signs-license-agreement-with-biorad-medisys-for-obalon-gastric-balloon
👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 2 weeks ago
$RSLS >>> Proof of patent!

Systems and methods for determining failure of intragastric devices
Patent number: 11730619
Abstract: Devices and methods for treating obesity are provided. More particularly, intragastric devices and methods of fabricating, deploying, inflating, locating, tracking, monitoring, deflating, and retrieving the same are provided.
Type: Grant
Filed: March 23, 2021
Date of Patent: August 22, 2023
Assignee: RESHAPE LIFESCIENCES INC.
Inventors: Mark C. Brister, Neil R. Drake, Antonio C. Llevares, Sheldon Nelson, Daniel J Proctor, Andrew P. Rasdal, Keoni John Sundseth, Amy D.L. VandenBerg, Betty Wong

Link: https://patents.justia.com/patents-by-us-classification/606/192
👍️0
S-BEES-BUMBLEBEE S-BEES-BUMBLEBEE 2 weeks ago
$RSLS https://ir.reshapelifesciences.com/news-releases/news-release-details/reshape-lifesciencesr-engages-maxim-group-llc-identify-strategic
👍️0
The Night Stalker The Night Stalker 2 weeks ago
https://stockcharts.com/h-sc/ui?s=rsls&p=D&yr=0&mn=5&dy=10&id=p24986097784&listNum=23&a=1113701411
👍️0

Your Recent History

Delayed Upgrade Clock